Literature DB >> 11462056

Effect of soluble CD4 on exposure of epitopes on primary, intact, native human immunodeficiency virus type 1 virions of different genetic clades.

H A Mbah1, S Burda, M K Gorny, C Williams, K Revesz, S Zolla-Pazner, P N Nyambi.   

Abstract

We have used a virus-binding assay to examine conformational changes that occur when soluble CD4 (sCD4) binds to the surface of intact, native, primary human immunodeficiency virus type 1 virions. The isolates examined belong to seven genetic clades (A to H) and are representative of syncytium-inducing and non-syncytium-inducing phenotypes. Conformational changes in epitopes in the C2, V2, V3, C5, and CD4 binding domain (CD4bd) of gp120 and the cluster I and II regions of gp41 of these viruses were examined using human monoclonal antibodies that are directed at these regions. The studies revealed that sCD4 binding causes a marked increase in exposure of epitopes in the V3 loop, irrespective of the clade or the phenotype of the virus. Sporadic increases in exposure were observed in some epitopes in the V2 region, while no changes were observed in the C2, C5, or CD4bd of gp120 or the cluster I and II regions of gp41.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11462056      PMCID: PMC115019          DOI: 10.1128/JVI.75.16.7785-7788.2001

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  27 in total

1.  Major glycoprotein antigens that induce antibodies in AIDS patients are encoded by HTLV-III.

Authors:  J S Allan; J E Coligan; F Barin; M F McLane; J G Sodroski; C A Rosen; W A Haseltine; T H Lee; M Essex
Journal:  Science       Date:  1985-05-31       Impact factor: 47.728

2.  Functional regions of the envelope glycoprotein of human immunodeficiency virus type 1.

Authors:  M Kowalski; J Potz; L Basiripour; T Dorfman; W C Goh; E Terwilliger; A Dayton; C Rosen; W Haseltine; J Sodroski
Journal:  Science       Date:  1987-09-11       Impact factor: 47.728

3.  The neutralization relationship of HIV type 1, HIV type 2, and SIVcpz is reflected in the genetic diversity that distinguishes them.

Authors:  P N Nyambi; B Willems; W Janssens; K Fransen; J Nkengasong; M Peeters; K Vereecken; L Heyndrickx; P Piot; G van der Groen
Journal:  AIDS Res Hum Retroviruses       Date:  1997-01-01       Impact factor: 2.205

4.  Conserved and exposed epitopes on intact, native, primary human immunodeficiency virus type 1 virions of group M.

Authors:  P N Nyambi; H A Mbah; S Burda; C Williams; M K Gorny; A Nádas; S Zolla-Pazner
Journal:  J Virol       Date:  2000-08       Impact factor: 5.103

5.  Host cell-dependent alterations in envelope components of human immunodeficiency virus type 1 virions.

Authors:  L Bastiani; S Laal; M Kim; S Zolla-Pazner
Journal:  J Virol       Date:  1997-05       Impact factor: 5.103

6.  Generation of neutralizing human monoclonal antibodies against parvovirus B19 proteins.

Authors:  A Gigler; S Dorsch; A Hemauer; C Williams; S Kim; N S Young; S Zolla-Pazner; H Wolf; M K Gorny; S Modrow
Journal:  J Virol       Date:  1999-03       Impact factor: 5.103

7.  Generation of human monoclonal antibodies to human immunodeficiency virus.

Authors:  M K Gorny; V Gianakakos; S Sharpe; S Zolla-Pazner
Journal:  Proc Natl Acad Sci U S A       Date:  1989-03       Impact factor: 11.205

8.  Macrophage and T cell-line tropisms of HIV-1 are determined by specific regions of the envelope gp120 gene.

Authors:  T Shioda; J A Levy; C Cheng-Mayer
Journal:  Nature       Date:  1991-01-10       Impact factor: 49.962

9.  Mapping of epitopes exposed on intact human immunodeficiency virus type 1 (HIV-1) virions: a new strategy for studying the immunologic relatedness of HIV-1.

Authors:  P N Nyambi; M K Gorny; L Bastiani; G van der Groen; C Williams; S Zolla-Pazner
Journal:  J Virol       Date:  1998-11       Impact factor: 5.103

10.  Antibodies that inhibit fusion of human immunodeficiency virus-infected cells bind a 24-amino acid sequence of the viral envelope, gp120.

Authors:  J R Rusche; K Javaherian; C McDanal; J Petro; D L Lynn; R Grimaila; A Langlois; R C Gallo; L O Arthur; P J Fischinger
Journal:  Proc Natl Acad Sci U S A       Date:  1988-05       Impact factor: 11.205

View more
  23 in total

1.  The v3 loop is accessible on the surface of most human immunodeficiency virus type 1 primary isolates and serves as a neutralization epitope.

Authors:  Miroslaw K Gorny; Kathy Revesz; Constance Williams; Barbara Volsky; Mark K Louder; Christopher A Anyangwe; Chavdar Krachmarov; Samuel C Kayman; Abraham Pinter; Arthur Nadas; Phillipe N Nyambi; John R Mascola; Susan Zolla-Pazner
Journal:  J Virol       Date:  2004-03       Impact factor: 5.103

2.  In vivo alteration of humoral responses to HIV-1 envelope glycoprotein gp120 by antibodies to the CD4-binding site of gp120.

Authors:  Maria Luisa Visciano; Michael Tuen; Miroslaw K Gorny; Catarina E Hioe
Journal:  Virology       Date:  2007-12-04       Impact factor: 3.616

3.  Structure determination of an anti-HIV-1 Fab 447-52D-peptide complex from an epitaxially twinned data set.

Authors:  Amandeep K Dhillon; Robyn L Stanfield; Miroslaw K Gorny; Constance Williams; Susan Zolla-Pazner; Ian A Wilson
Journal:  Acta Crystallogr D Biol Crystallogr       Date:  2008-06-18

4.  Soluble CD4 broadens neutralization of V3-directed monoclonal antibodies and guinea pig vaccine sera against HIV-1 subtype B and C reference viruses.

Authors:  Xueling Wu; Anna Sambor; Martha C Nason; Zhi-Yong Yang; Lan Wu; Susan Zolla-Pazner; Gary J Nabel; John R Mascola
Journal:  Virology       Date:  2008-09-18       Impact factor: 3.616

5.  Crystal structures of human immunodeficiency virus type 1 (HIV-1) neutralizing antibody 2219 in complex with three different V3 peptides reveal a new binding mode for HIV-1 cross-reactivity.

Authors:  Robyn L Stanfield; Miroslaw K Gorny; Susan Zolla-Pazner; Ian A Wilson
Journal:  J Virol       Date:  2006-06       Impact factor: 5.103

6.  Structural analysis of human and macaque mAbs 2909 and 2.5B: implications for the configuration of the quaternary neutralizing epitope of HIV-1 gp120.

Authors:  Brett Spurrier; Jared M Sampson; Maxim Totrov; Huiguang Li; Timothy O'Neal; Constance Williams; James Robinson; Miroslaw K Gorny; Susan Zolla-Pazner; Xiang-Peng Kong
Journal:  Structure       Date:  2011-05-11       Impact factor: 5.006

7.  Antibody responses elicited in macaques immunized with human immunodeficiency virus type 1 (HIV-1) SF162-derived gp140 envelope immunogens: comparison with those elicited during homologous simian/human immunodeficiency virus SHIVSF162P4 and heterologous HIV-1 infection.

Authors:  Nina R Derby; Zane Kraft; Elaine Kan; Emma T Crooks; Susan W Barnett; Indresh K Srivastava; James M Binley; Leonidas Stamatatos
Journal:  J Virol       Date:  2006-09       Impact factor: 5.103

8.  SERINC5 Inhibits HIV-1 Infectivity by Altering the Conformation of gp120 on HIV-1 Particles.

Authors:  Austin Featherstone; Christopher Aiken
Journal:  J Virol       Date:  2020-09-29       Impact factor: 5.103

Review 9.  Structure-function relationships of HIV-1 envelope sequence-variable regions refocus vaccine design.

Authors:  Susan Zolla-Pazner; Timothy Cardozo
Journal:  Nat Rev Immunol       Date:  2010-07       Impact factor: 53.106

10.  A broad range of mutations in HIV-1 neutralizing human monoclonal antibodies specific for V2, V3, and the CD4 binding site.

Authors:  Liuzhe Li; Xiao-Hong Wang; Constance Williams; Barbara Volsky; Olivia Steczko; Michael S Seaman; Kalpana Luthra; Phillipe Nyambi; Arthur Nadas; Véronique Giudicelli; Marie-Paule Lefranc; Susan Zolla-Pazner; Miroslaw K Gorny
Journal:  Mol Immunol       Date:  2015-05-18       Impact factor: 4.407

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.